2004
Regulatory T cells in type 1 diabetes mellitus
Viglietta V, Baecher-Allan C, Hafler A, Gottlieb P. Regulatory T cells in type 1 diabetes mellitus. Current Opinion In Endocrinology Diabetes And Obesity 2004, 11: 85-90. DOI: 10.1097/01.med.0000129641.34639.2e.Peer-Reviewed Original ResearchRegulatory T cellsType 1 diabetes mellitusType 1 diabetesT cellsDiabetes mellitusT lymphocytesHuman type 1 diabetesΒ-cell antigensNK T cellsTh2-type responseMost healthy subjectsReactive T lymphocytesOnset of diseaseInsulin-producing β-cellsAutoimmune conditionsPeripheral toleranceRegulatory cellsPeripheral deletionSpecific immunizationTh2 cytokinesAutoimmune diseasesHealthy subjectsAntigen reactivityHealthy individualsAnergy induction
1998
Pulse Cyclophosphamide Plus Methylprednisolone Induces Myelin-Antigen-Specific IL-4-Secreting T Cells in Multiple Sclerosis Patients
Takashima H, Smith D, Fukaura H, Khoury S, Hafler D, Weiner H. Pulse Cyclophosphamide Plus Methylprednisolone Induces Myelin-Antigen-Specific IL-4-Secreting T Cells in Multiple Sclerosis Patients. Clinical Immunology 1998, 88: 28-34. PMID: 9683547, DOI: 10.1006/clin.1998.4558.Peer-Reviewed Original ResearchConceptsIL-4-secreting T cellsUntreated MS patientsProgressive MS patientsT cell linesMS patientsIL-4 secretionMyelin basic proteinT cellsMultiple sclerosisMyelin antigensTetanus toxoidTh1-type autoimmune diseaseShort-term T cell linesCell linesPulse cyclophosphamide therapyTh2-type responseIL-4 productionMultiple sclerosis patientsIFN-gamma productionProteolipid proteinImmune deviationPulse cyclophosphamideCyclophosphamide therapySclerosis patientsAutoimmune diseases
1997
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophilia
Smith D, Balashov K, Hafler D, Khoury S, Weiner H. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophilia. Annals Of Neurology 1997, 42: 313-318. PMID: 9307252, DOI: 10.1002/ana.410420307.Peer-Reviewed Original ResearchConceptsMonthly intravenous methylprednisolonePulse cyclophosphamide therapyMultiple sclerosisImmune deviationIL-4Cyclophosphamide therapyIFN-beta1bMS patientsHealthy controlsTh1-type cell-mediated autoimmune diseaseCell-mediated autoimmune diseaseMethotrexate-treated patientsT-cell interferonUntreated MS patientsUntreated multiple sclerosisPeripheral blood eosinophiliaProgressive MS patientsTh2-type responseCyclophosphamide-treated patientsIL-10 productionInterleukin-4 productionMinimal IL-4Intravenous cyclophosphamideIntravenous methylprednisoloneBlood eosinophilia
1994
Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens
Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. Annual Review Of Immunology 1994, 12: 809-837. PMID: 8011298, DOI: 10.1146/annurev.iy.12.040194.004113.Peer-Reviewed Original ResearchConceptsOrgan-specific autoimmune diseasesExperimental autoimmune encephalomyelitisAntigen-specific fashionOral toleranceRegulatory cellsSuppressive cytokinesAutoimmune diseasesClonal anergyHuman organ-specific autoimmune diseasesGut-associated lymphoid tissueAntigen-nonspecific fashionExperimental autoimmune modelsTh2-type responsePositive clinical effectsProlong graft survivalPeripheral immune toleranceT cell autoreactivityInitial clinical trialsAntigen-induced toleranceActive suppressionOral tolerizationSuppress alloreactivityGraft survivalNOD miceAutoimmune encephalomyelitis